Incyte Corporation

This study tested several different drug combinations given before bladder removal surgery to patients with muscle-invasive bladder cancer who couldn't take standard cisplatin chemotherapy. The goal was to see how these treatments affected immune cells in the tumor and whether th…

This study tested whether combining three different cancer drugs was safe and could help control advanced solid tumors that had stopped responding to other treatments. It involved 70 people with cancers like advanced lung cancer and colorectal cancer. The goal was to see if this …

This study tested different doses of the drug ruxolitinib for patients with two types of blood cell disorders (polycythemia vera and essential thrombocythemia) who could not tolerate or did not respond to standard treatment. The goal was to find the safest and most effective dose…

This early-stage study tested the safety and highest tolerable dose of an experimental drug called INCB062079 in people with advanced liver cancer and other solid tumors. The trial enrolled 25 participants whose cancers had progressed after standard treatments and was designed to…

This study tested whether adding a new drug called parsaclisib to an existing treatment (ruxolitinib) could better control myelofibrosis, a serious bone marrow cancer. It involved 252 adults with intermediate or high-risk disease who had not previously taken similar medications. …

This study aimed to test the safety and effectiveness of a new drug, itacitinib, when given with standard steroids to children who developed a serious complication called acute graft-versus-host disease after a stem cell transplant. The trial was designed for children and teens w…

This study tested whether a medication called parsaclisib could help people with warm autoimmune hemolytic anemia (wAIHA), a rare condition where the immune system attacks red blood cells. The trial compared parsaclisib against a placebo (inactive pill) in 13 participants over 24…

This study tested whether the drug pemigatinib could help control recurrent brain tumors that have specific genetic changes in the FGFR genes. The trial included about 83 adults with glioblastoma or other brain tumors that had returned after previous treatments. Participants took…

This study aimed to test the safety and effectiveness of adding a new drug called INCB001158 to an existing myeloma treatment (daratumumab) for people whose cancer has come back or stopped responding to other therapies. It involved 15 participants and compared the combination to …

This study aimed to see if a new drug combination (pemigatinib plus pembrolizumab) worked better than standard care for people with advanced bladder cancer who cannot take cisplatin and have a specific genetic change (FGFR3). It was a Phase 2 trial that was terminated early, enro…

This early-stage study tested a new drug called INCA00186, given alone or combined with other immunotherapy drugs, in people with advanced head/neck cancers or certain gastrointestinal cancers. The main goals were to check the safety of the drug, find the right dose, and see if i…

This early-stage study tested a new drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety, how the body processes it, and what side effects it might cause. The trial was termina…

This early-phase study aimed to see if combining two targeted drugs, tafasitamab and parsaclisib, was safe and effective for adults whose non-Hodgkin lymphoma or chronic lymphocytic leukemia had returned or stopped responding to prior treatments. The trial enrolled 54 participant…

This early-stage study tested a drug called itacitinib for people who developed a serious lung complication called BOS after a double lung transplant. The main goals were to check the drug's safety and see if it could help improve or stabilize patients' breathing. The trial invol…

This early-stage study tested a new drug called INCB059872 in people with advanced cancers that had few treatment options. The main goals were to find a safe dose and see what side effects occurred, both when the drug was given alone and when combined with other cancer medication…

This early-phase study tested a new drug called INCB000928 to see if it could safely treat anemia (low red blood cells) in people with myelodysplastic syndromes (MDS) or multiple myeloma. The main goals were to find a safe dose and see if the drug could reduce the need for blood …

This study tested whether adding the experimental drug itacitinib to standard steroid treatment could better control chronic graft-versus-host disease (cGVHD) in people who had stem cell transplants. Researchers enrolled 155 participants with moderate to severe cGVHD who hadn't r…

This early-stage study tested the safety of an experimental drug called INCB081776, both alone and combined with another drug, in people with advanced cancers that had stopped responding to standard treatments. The main goal was to find safe dosage levels and understand how the b…

This study tested whether adding the experimental drug itacitinib to standard preventive medications could better protect patients from graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. It involved 84 participants who were eligible for a reduced-int…

This early-phase study aimed to find a safe dose and check the side effects of a new drug called INCB057643 for people with advanced cancers that had stopped responding to other treatments. It tested the drug alone and combined with standard treatments in about 137 participants w…

This early-stage study tested the safety and initial effects of an experimental drug called INCB059872 in 25 people with advanced Ewing sarcoma, a rare bone and soft tissue cancer. Participants had cancer that returned or didn't respond to standard treatments and had no other cur…

This study tested whether adding a new drug called parsaclisib to the standard treatment (ruxolitinib) could help people with myelofibrosis, a serious bone marrow cancer, who weren't getting a good enough response from ruxolitinib alone. It involved 177 participants and compared …

This study tested whether the drug pemigatinib could help control advanced solid tumors that had specific genetic changes (FGFR mutations or fusions) and had stopped responding to other treatments. It involved 111 adults whose cancer had spread or could not be removed by surgery.…

This study tested whether applying a prescription cream called ruxolitinib could help adults with atopic dermatitis (eczema) sleep better. It focused on people whose eczema itch was significantly disturbing their sleep. Researchers measured changes in total sleep time and sleep q…

This early-stage study aimed to check the safety and see how the body processes a new oral drug called INCB000631. It involved 24 healthy adults who received either the drug or a placebo. The main goals were to find safe dose levels and measure how much of the drug gets into the …